Domov › Rak jajčnikov › Oregon › Portland
Klinične študije za Rak jajčnikov v Portland, OR
27 študij za Rak jajčnikov išče udeležence na lokacijah v Portland in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
Vključevanje udeležencevFaza 3
- Providence Cancer Institute, Portland
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
Vključevanje udeležencevFaza 2/3
- Oregon Health and Science University, Portland
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Vključevanje udeležencevFaza 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Vključevanje udeležencevFaza 1/2
- Research Site, Portland
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Vključevanje udeležencevFaza 1/2
- Oregon Health & Science University (OHSU), Portland
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Vključevanje udeležencevFaza 2
- Providence Portland Medical Center /ID# 277727, Portland
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- Site 02, Portland
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Vključevanje udeležencevFaza 1
- Research Site, Portland
Study of AVZO-021 in Patients With Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- Avenzo Therapeutics Recruiting Site, Portland
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Vključevanje udeležencevFaza 3
- Providence Portland Medical Center, Portland
- Kaiser Permanente Interstate Medical Office Central, Portland
- Oregon Health and Science University, Portland
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Vključevanje udeležencevFaza 3
- Providence Cancer Institute Franz Clinic, Portland
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Vključevanje udeležencevFaza 2
- Providence Cancer Institute, Portland
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Vključevanje udeležencevFaza 1
- Providence Portland Medical Center, Portland
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- Providence Cancer Center Oncology and Hematology Care- Eastside, Portland
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
Vključevanje udeležencevFaza 3
- Site 0105, Portland
A Study of MGC026 in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- Providence Cancer Institute, Portland
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Vključevanje udeležencev
- Legacy Good Samaritan Hospital and Medical Center, Portland
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- in še 2
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Vključevanje udeležencevFaza 3
- Legacy Good Samaritan Hospital and Medical Center, Portland
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- in še 2
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Vključevanje udeležencevFaza 1/2
- Compass Oncology - Rose Quarter, Portland
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Vključevanje udeležencevFaza 1/2
- Oregon Health & Science University, Portland
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Vključevanje udeležencevFaza 1/2
- Providence Cancer Institute Franz Clinic, Portland
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Vključevanje udeležencevFaza 1
- Providence Cancer Institute Franz Clinic, Portland
- Providence Oncology and Hematology Care Clinic - Westside, Portland
- Providence St. Vincent Medical Center- Investigational Drug Services, Portland
- in še 1
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Vključevanje udeležencevFaza 3
- Legacy Medical Group Gynecologic Oncology, Portland
- Providence Cancer Center Oncology, Portland
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Vključevanje udeležencevFaza 2
- USA15-0, Portland
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
- Oregon Health Sciences University, Portland
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Vključevanje udeležencevFaza 2
- SCRI - Northwest Cancer Specialists, P.C., Portland
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Vključevanje udeležencevOpazovalna študija
- Massive Bio SYNERGY-AI site, Portland
Študije za Rak jajčnikov v drugih mestih
- Houston, TX89 študij
- New York City, NY69 študij
- Boston, MA61 študij
- Los Angeles, CA50 študij
- Nashville, TN49 študij
- Arlington, VA46 študij
- Philadelphia, PA44 študij
- Columbus, OH39 študij
- St. Louis, MO38 študij
- Chicago, IL36 študij
- San Antonio, TX31 študij
- Cleveland, OH30 študij
Druge študije v Portland
- Nemalicelični pljučni rak46 študij
- Rak (vse vrste)34 študij
- Rak dojke33 študij
- Rak prostate33 študij
- Metastatski rak29 študij
- Kolorektalni rak28 študij
- Rak pljuč26 študij
- Akutna mieločna levkemija25 študij
- Rak endometrija24 študij
- Ploščatocelični karcinom glave in vratu19 študij
- Rak trebušne slinavke19 študij
- Srčno popuščanje17 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.